7 Top Gainers In Healthcare Sector (ALRN, APHA, INSY...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Aileron Therapeutics Inc. (ALRN)

Aileron is a clinical-stage company developing therapies to treat cancer and other diseases.

Gained 21.88% to close Monday's (Feb.4) trading at $1.73.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase IIa expansion of ALRN-6924 as monotherapy in cohorts of patients with relapsed or refractory peripheral T-cell lymphoma is underway. Interim data reported last December were promising. -- A phase IIa expansion cohort of ALRN-6924 in combination with Pfizer's IBRANCE in cancer patients with MDM2-amplified solid tumors is ongoing. Preliminary data from this trial is expected in the second half of 2019. -- A phase I and phase Ib open-label, multi-center dose-escalation trials of ALRN-6924 as a monotherapy and in combination with cytosine arabinoside (Ara-C) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) and patients with myelodysplastic syndrome (MDS) who failed hypomethylating agents are ongoing. Interim data reported last December were promising.

2. Eyenovia Inc. (EYEN)

Eyenovia is a clinical stage, ophthalmic biopharmaceutical company.

Gained 18.18% to close Monday's trading at $3.90.

News: No news

Recent event:

-- On January 30, the Company announced that its phase III study evaluating MicroStat for pharmacologic mydriasis (eye dilation), dubbed MIST-1, met the primary endpoint.

The second phase III study in the MicroStat program for pharmacologic mydriasis, dubbed MIST-2 study, is underway, with results "expected to be announced in short order".

3. Therapix Biosciences Ltd. (TRPX)

Therapix Biosciences is a Canada-based specialty clinical-stage pharmaceutical company developing unique cannabinoid technologies for the treatment of central nervous system disorders.

Gained 16.62% to close Monday's trading at $4.49.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase IIa trial of THX-110 for the treatment of Obstructive Sleep Apnea is underway, with top-line results expected in the first half of 2019. -- A phase IIb clinical trial for THX-110 in Tourette syndrome is ongoing, and top-line results are expected in the second half of 2020.

4. Constellation Pharmaceuticals Inc. (CNST)

Constellation Pharma is a clinical-stage biopharmaceutical company developing next-generation epigenetic treatments for cancer patients.

Gained 15.83% to close Monday's trading at $8.78.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase II trial of CPI-0610 in myelofibrosis, dubbed MANIFEST, is ongoing. Interim data update of this trial is expected in Q2, 2019. -- A phase Ib/II trial of CPI-1205 in metastatic castration-resistant prostate cancer (mCRPC) in combination with either abiraterone or enzalutamide, dubbed ProSTAR, is underway. Data from phase Ib portion of the trial is anticipated in Q2, 2019. -- A phase I study of CPI-0209 in solid tumors is expected to be initiated in mid-2019.

5. INSYS Therapeutics Inc. (INSY)

Gained 15.74% to close Monday's trading at $3.97.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase II trial of Cannabidiol oral solution in childhood absence epilepsy is ongoing. Data read-out from this trial is expected in Q1, 2019. -- A phase II trial of Cannabidiol oral solution in Prader-Willi syndrome is underway. Data read-out from this trial is expected in Q4, 2019. -- A phase III trial of Cannabidiol oral solution in infantile spasms is ongoing. -- File NDA for Epinephrine nasal spray product in Anaphylaxis in Q4, 2019. -- Report results from nonclinical juvenile toxicity study related to Naloxone in early March of 2019. -- File NDA for Naloxone nasal spray for opioid overdose in Q1, 2019.

6. Arvinas Holding Co. LLC (ARVN)

Gained 13.96% to close Monday's trading at $20.49.

News: No news

Recent event:

The Company went public on the Nasdaq Global Select Market on September 27, 2018, at an offering price of $16.00 per share.

Clinical trials & Near-term Catalysts:

The most advanced drug candidate in the pipeline is ARV-110 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Arvinas expects to begin enrollment of a Phase 1 clinical trial for ARV-110 in the first quarter of this year.

7. Aphria Inc. (APHA)

Aphria is a global cannabis company.

Gained 12.68% to close Monday's trading at $10.84.

News: No news

Recent events:

-- On February 1, the Company introduced the first four Aphria cannabis strains to be produced in Europe, through its strategic alliance with Denmark-based Schroll Medical. - On January 22, the Company confirmed an unsolicited take-over bid by Green Growth Brands Inc. (GGB.CN) and urged the shareholders to take no action. -- On January 11, the Company reported fiscal 2019 second quarter financial results.

Net income for the second quarter ended November 30, 2018, was $54.8 million or $0.22 per share compared to $6.5 million or $0.05 per share for the same period last year. Net revenue for the fiscal 2019 second quarter was $21.7 million compared to $8.5 million in the same period last year.